Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective, Mathew W. MacCumber, MD, PhD, discusses his poster presentation from the ...

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the ...

ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the ...

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator ...

For author information and disclosures, see end of text. The most common complication of NIU and the primary condition associated with vision loss in uveitis is macular edema (ME), a central ...

Clearside Biomedical presented data on CLS-AX and its SCS delivery platform at the ARVO 2025 Meeting, highlighting treatment advancements for retinal diseases. Clearside Biomedical, Inc. has announced ...

BioCryst Pharmaceuticals, Inc., a global biotechnology company, and Clearside Biomedical, Inc., announced the entry into a license agreement enabling BioCryst to develop its investigational plasma ...

Single-cell microinjection represents an innovative way to integrate exogenous material into cells and to extract and transmit cellular components between cells. The effectiveness of any ...

- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced plans to explore a full range ...